-+ 0.00%
-+ 0.00%
-+ 0.00%

IPO News | Yinuo Weimedicine submits listing for the third time on the Hong Kong Stock Exchange

Zhitongcaijing·07/16/2026 10:41:13
Listen to the news

Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on July 16, Immvira Bioscience Inc. (abbreviation: Inuowei Pharmaceuticals) submitted a listing application to the main board of the Hong Kong Stock Exchange, with Citibank and CICC as co-sponsors. According to the prospectus, Inuowei Pharmaceutical is a biotechnology company focusing on clinical needs. It is committed to the discovery, development, production and commercialization of novel oncolytic immunotherapy and engineered exosome therapies. The company has established a product pipeline, including two tumolytic immunotherapy products for solid tumors and five engineered exosome products with clinical application prospects or direct commercialization.

image.png